EUVIMEDEUVIMED entdecken
Klinische Studie (Phase I)Multizentrische Studie

A phase I, first-in-human dose-escalation and triple-negative breast cancer dose-expansion study of a TROP2-ADC F0024 (FDA018)

Yiqun Du, Yanchun Meng, Xiaojun Liu, Jingfen Wang, Ying Wang, Fan Wu, Yu Chen, Lilin Chen, Lihua Qing, Wenyi Sun, Kezhen Liu, Jian Zhang

European Journal of Cancer · 2026-11 · 248 · 117063

DOI: 10.1016/j.ejca.2026.117063 ↗

Kurz gefasst

Klinische Studie (Phase I) in der Zeitschrift European Journal of Cancer, 2026-11. Verfasst von Yiqun Du und 11 weiteren Autor:innen. Beteiligte Einrichtung: Phase I Unit, Fudan University Shanghai Cancer Center, Shanghai, China; Department of Oncology, Shanghai Medical College, Fudan University, Shanghai,…. Hauptthemen laut MEDLINE: Triple Negative Breast Neoplasms, Antigens, Neoplasm, Cell Adhesion Molecules, Antineoplastic Agents. Die Arbeit nennt 28 Literaturangaben. Gefördert von: Science and Technology Commission of Shanghai Municipality.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Kein Abstract verfügbar.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Triple Negative Breast NeoplasmsAntigens, NeoplasmCell Adhesion MoleculesAntineoplastic AgentsHumansFemaleAdultMiddle AgedAgedDose-Response Relationship, DrugAged, 80 and overMaximum Tolerated Dose

Stichwörter der Autor:innen

Antibody-drug conjugateF0024FDA018First-in-humanTROP2Triple-negative breast cancer

Substanzen

TACSTD2 protein, humanAntigens, NeoplasmCell Adhesion MoleculesAntineoplastic Agents

Autor:innen und Institutionen

  • Phase I Unit, Fudan University Shanghai Cancer Center, Shanghai, China; Department of Oncology, Shanghai Medical College, Fudan University, Shanghai, China.
  • Department II of Breast, Linyi Cancer Hospital, Linyi, China.
  • Sun Yat-sen Memorial Hospital, Sun Yat-sen University, Guangzhou, China.
  • Department of Medical Oncology, Fujian Cancer Hospital, Fuzhou, China.
  • Phase I Unit, Fujian Cancer Hospital, Fuzhou, China.
  • Department of Medical Oncology, The First Affiliated Hospital of Xiamen University, Xiamen, China.

Förderung

  • Science and Technology Commission of Shanghai Municipality

Zitieren

APA

Du, Y., Meng, Y., Liu, X., Wang, J., Wang, Y., Wu, F., Chen, Y., Chen, L., Qing, L., Sun, W., Liu, K., & Zhang, J. (2026). A phase I, first-in-human dose-escalation and triple-negative breast cancer dose-expansion study of a TROP2-ADC F0024 (FDA018). European Journal of Cancer, 248, 117063. https://doi.org/10.1016/j.ejca.2026.117063

Vancouver

Du Y, Meng Y, Liu X, Wang J, Wang Y, Wu F, et al. A phase I, first-in-human dose-escalation and triple-negative breast cancer dose-expansion study of a TROP2-ADC F0024 (FDA018). European Journal of Cancer. 2026;248:117063. doi:10.1016/j.ejca.2026.117063

BibTeX
@article{Du2026,
  author = {Du, Yiqun and Meng, Yanchun and Liu, Xiaojun and Wang, Jingfen and Wang, Ying and Wu, Fan and Chen, Yu and Chen, Lilin and Qing, Lihua and Sun, Wenyi and Liu, Kezhen and Zhang, Jian},
  title = {A phase I, first-in-human dose-escalation and triple-negative breast cancer dose-expansion study of a TROP2-ADC F0024 (FDA018)},
  journal = {European Journal of Cancer},
  year = {2026},
  volume = {248},
  pages = {117063},
  doi = {10.1016/j.ejca.2026.117063}
}
Kostenlos starten →